MCID: NPH018
MIFTS: 51

Nephrogenic Systemic Fibrosis malady

Categories: Rare diseases, Skin diseases, Nephrological diseases

Aliases & Classifications for Nephrogenic Systemic Fibrosis

About this section
Sources:
46NIH Rare Diseases, 52Orphanet, 66UMLS, 67UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Nephrogenic Systemic Fibrosis:

Name: Nephrogenic Systemic Fibrosis 46 52 66
Nephrogenic Fibrosing Dermopathy 46 52 66
 
Nsf 46
Nfd 46

Classifications:

Orphanet: 52 
Rare skin diseases


External Ids:

Orphanet52 ORPHA137617
UMLS via Orphanet67 C1619692

Summaries for Nephrogenic Systemic Fibrosis

About this section
NIH Rare Diseases:46 Nephrogenic systemic fibrosis is a condition that affects different parts of the body, particularly the skin. symptoms of the condition may include progressive swelling and tightening of the skin, sometimes resulting in contractures, and pruritis (itching).  the skin findings are similar to those seen in patients with scleroderma.  nephrogenic systemic fibrosis was first described in 1997. being exposed to gadolinium-containing contrast agents during mri testing has been identified as a significant risk factor for development of this disease. last updated: 4/24/2013

MalaCards based summary: Nephrogenic Systemic Fibrosis, also known as nephrogenic fibrosing dermopathy, is related to neuronal intranuclear inclusion disease and tetanus, and has symptoms including exanthema, pruritus and skin manifestations. An important gene associated with Nephrogenic Systemic Fibrosis is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways are Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers and ALK1 signaling events. Affiliated tissues include skin, kidney and eye, and related mouse phenotypes are muscle and respiratory system.

Wikipedia:69 Nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD) is a rare and serious... more...

Related Diseases for Nephrogenic Systemic Fibrosis

About this section

Diseases related to Nephrogenic Systemic Fibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 71)
idRelated DiseaseScoreTop Affiliating Genes
1neuronal intranuclear inclusion disease11.3
2tetanus11.1
3n syndrome10.9
4foodborne botulism10.9
5congenital fibrosis of the extraocular muscles 1a10.7EDNRA, TGFB1
646 xy gonadal dysgenesis10.6EDN1, TGFB1, TIMP1
7burn scar10.5EDN1, TGFB1, TIMP1
8lymphogranuloma venereum10.5CTGF, TGFB1
9bubonic plague10.5EDN1, EDNRA, TGFB1
10gingivitis10.5EDN1, TGFB1, TIMP1
11salt and pepper syndrome10.4CTGF, TGFB1, TIMP1
12echinococcosis10.4CTGF, TGFB1, TIMP1
13granulomatous orchitis10.4CTGF, TGFB1, TIMP1
14hodgkin's lymphoma, lymphocytic-histiocytic predominance10.4CTGF, EDN1, TGFB1
15paranasal sinus sarcoma10.4CTGF, TGFB1, TIMP1
16iga glomerulonephritis10.4EDN1, EDNRA
17nonspecific interstitial pneumonia10.3CTGF, EDN1, TGFB1
18exudative vitreoretinopathy 110.3CTGF, TGFB1, TIMP1
19kidney disease10.3
20gemistocytic astrocytoma10.3EDN1, EPO, TGFB1, TIMP1
21lymphedema10.3EDN1, TGFB1, TIMP1
22hyperekplexia 2, autosomal recessive10.3EDN1, EDNRA
23temporomandibular ankylosis10.2CTGF, EDN1, TGFB1
24mononeuritis10.2CTGF, EDN1, EPO, TGFB1
25liver disease10.1
26gallbladder papillomatosis10.1PIK3CA, SMAD4, TGFB1
27renal dysplasia, bilateral10.1CTGF, SMAD2
28vitreous abscess10.0CTGF, SMAD2, TGFB1
29grn-related frontotemporal dementia10.0
30myelitis10.0CCL7, CXCL2, SPP1
31sarcoma10.0
32retinitis pigmentosa9.9
33retinitis9.9
34neuronitis9.9
35cocaine dependence9.9
36keratopathy9.8SMAD3, TGFB1
37kaposi sarcoma9.8
38atherosclerosis9.8
39hepatitis9.8
40keloids9.8
41spinal cord injury9.8
42lymphoma9.8
43respiratory failure9.8
44hypercalcemia9.8
45pure red-cell aplasia9.8
46hypothyroidism9.8
47panniculitis9.8
48myopathy9.8
49histiocytoma9.8
50fibrous histiocytoma9.8

Graphical network of the top 20 diseases related to Nephrogenic Systemic Fibrosis:



Diseases related to nephrogenic systemic fibrosis

Symptoms for Nephrogenic Systemic Fibrosis

About this section

UMLS symptoms related to Nephrogenic Systemic Fibrosis:


exanthema, pruritus, skin manifestations, uraemia odour

Drugs & Therapeutics for Nephrogenic Systemic Fibrosis

About this section

Drugs for Nephrogenic Systemic Fibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1Imatinib MesylatePhase 3, Phase 2588123596
2
Iodine5167553-56-2807
Synonyms:
I2
Iode
Iodine-molecule
 
Iodio
Iodum
Jod
Jood
Tincture iodine
3cadexomer iodine484

Interventional clinical trials:

(show all 23)
idNameStatusNCT IDPhase
1Primovist / Eovist in Renally Impaired PatientsCompletedNCT00908596Phase 4
2Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of MagnevistCompletedNCT00744939Phase 4
3Safety of Gadovist in Renally Impaired PatientsCompletedNCT00828737Phase 4
4Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)CompletedNCT00908310Phase 4
5Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart DiseaseRecruitingNCT02752191Phase 4
6Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF)TerminatedNCT01078987Phase 4
7Treatment of Patients With Nephrogenic Systemic Fibrosis With GlivecCompletedNCT00981942Phase 3
8Efficacy and Safety of Primovist in Chinese PatientsCompletedNCT00526188Phase 3
9Nephrogenic Systemic Fibrosis With GadollinumEnrolling by invitationNCT01359345Phase 2, Phase 3
10The Effect of Crystalloids and Colloids on Visceral Blood FlowCompletedNCT01087853Phase 1, Phase 2
11Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic FibrosisActive, not recruitingNCT00677092Phase 2
12Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium LevelsCompletedNCT01014754
13Validation of a Questionnaire to Identify Signs and Symptoms of Nephrogenic Systemic FibrosisCompletedNCT00869479
14Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MRCompletedNCT01135316
15Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)CompletedNCT00773409
16Magnevist Post-marketing Surveillance in JapanCompletedNCT01376739
17Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney DiseaseCompletedNCT00600834
18Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney DiseaseCompletedNCT00600951
19Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study)CompletedNCT01523873
20Adverse Reactions to MR and CT-examinations (Enhanced and Unenhanced)CompletedNCT01132339
21Pilot Study of the Effect of Laser on Reversing Chronic Radiation InjuryRecruitingNCT01910818
22Observational Study on the Incidence of NSF in Renal Impaired Patients Following DOTAREM AdministrationActive, not recruitingNCT01467271
23Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK InjectionSuspendedNCT00811863

Search NIH Clinical Center for Nephrogenic Systemic Fibrosis

Genetic Tests for Nephrogenic Systemic Fibrosis

About this section

Anatomical Context for Nephrogenic Systemic Fibrosis

About this section

MalaCards organs/tissues related to Nephrogenic Systemic Fibrosis:

34
Skin, Kidney, Eye, Testes, Liver, Heart, Bone

Animal Models for Nephrogenic Systemic Fibrosis or affiliated genes

About this section

MGI Mouse Phenotypes related to Nephrogenic Systemic Fibrosis:

39 (show all 20)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053698.4DCN, EDN1, EDNRA, EPO, PIK3CA, SMAD4
2MP:00053888.2CTGF, DCN, EDNRA, EPO, F13A1, SMAD2
3MP:00053678.1DCN, EDN1, EDNRA, SMAD3, SMAD4, SPP1
4MP:00028738.1CTGF, DCN, EDN1, EDNRA, EPO, SMAD2
5MP:00020068.1DCN, PIK3CA, SMAD2, SMAD3, SMAD4, SPP1
6MP:00053918.0CTGF, DCN, EDNRA, MAPKAP1, PIK3CA, SMAD2
7MP:00053827.7CTGF, DCN, EDN1, EDNRA, SMAD2, SMAD3
8MP:00053817.7CTGF, DCN, EDN1, EDNRA, SMAD2, SMAD3
9MP:00053807.6CTGF, EDN1, EDNRA, EPO, PIK3CA, SMAD2
10MP:00053897.6DCN, F13A1, PIK3CA, SMAD2, SMAD3, SMAD4
11MP:00107717.5CTGF, DCN, EDNRA, EPO, PIK3CA, SMAD2
12MP:00053877.3DCN, EDNRA, EPO, PIK3CA, SMAD2, SMAD3
13MP:00053797.3DCN, EDN1, EDNRA, PIK3CA, SMAD2, SMAD3
14MP:00053907.2CTGF, DCN, EDN1, EDNRA, PIK3CA, SMAD2
15MP:00053977.0DCN, EDNRA, EPO, F13A1, SMAD2, SMAD3
16MP:00053846.9CTGF, DCN, EDNRA, EPO, MAPKAP1, PIK3CA
17MP:00053786.5CTGF, DCN, EDN1, EDNRA, PIK3CA, SMAD2
18MP:00107685.8CTGF, DCN, EDN1, EDNRA, EPO, F13A1
19MP:00053765.6CTGF, DCN, EDN1, EDNRA, EPO, F13A1
20MP:00053855.3CTGF, CXCL2, EDN1, EDNRA, EPO, F13A1

Publications for Nephrogenic Systemic Fibrosis

About this section

Articles related to Nephrogenic Systemic Fibrosis:

(show top 50)    (show all 414)
idTitleAuthorsYear
1
Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium - 1997-2006-2016. Part 1. (26802069)
2016
2
Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis. (25654421)
2015
3
Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. (24706993)
2014
4
Substitution of gadolinium ethylenediaminetetraacetate with phosphites: towards gadolinium deposit in nephrogenic systemic fibrosis. (24132302)
2013
5
Nephrogenic systemic fibrosis in denmark- a nationwide investigation. (24349178)
2013
6
Contrast-induced nephropathy and nephrogenic systemic fibrosis: minimizing the risk. (22316507)
2012
7
Nephrogenic systemic fibrosis: evidence for oxidative stress and bone marrow-derived fibrocytes in skin, liver, and heart lesions using a 5/6 nephrectomy rodent model. (23041060)
2012
8
Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. (21036418)
2011
9
Nephrogenic systemic fibrosis: a brief review. (21572794)
2011
10
"Carcinoid-like" tricuspid valvulopathy associated with nephrogenic systemic fibrosis. (21366687)
2011
11
Detection of iron deposition in dermal fibrocytes is a useful tool for histologic diagnosis of nephrogenic systemic fibrosis. (21389836)
2011
12
Gadolinium deposition in nephrogenic systemic fibrosis: an examination of tissue using synchrotron x-ray fluorescence spectroscopy. (19896750)
2010
13
Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network. (20032228)
2010
14
Nephrogenic systemic fibrosis: a review. (20677539)
2010
15
Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: a disorder of aberrant dermal remodeling. (19341434)
2010
16
Nephrogenic systemic fibrosis in a patient with spinal cord injury: a unique case presentation. (21145526)
2010
17
NFI_B activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. (20959327)
2010
18
MRI safety: nephrogenic systemic fibrosis and other risks. (20542435)
2010
19
Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions. (20430497)
2010
20
Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis? (19939504)
2010
21
Nephrogenic systemic fibrosis: report of an additional case with granulomatous inflammation. (19940755)
2010
22
Nephrogenic systemic fibrosis: a concise review for cardiologists. (20978560)
2010
23
The German registry for nephrogenic systemic fibrosis: findings from 23 patients. (20497754)
2010
24
Nephrogenic systemic fibrosis: clinical picture and treatment. (19744598)
2009
25
High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: Prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function. (19457816)
2009
26
Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. (19789237)
2009
27
Nephrogenic systemic fibrosis in a Chinese renal-transplant recipient. (19120400)
2009
28
Nephrogenic systemic fibrosis: the need for accurate case reporting. (19388104)
2009
29
The evolution of osseous metaplasia in localized cutaneous nephrogenic systemic fibrosis: a case report. (19633532)
2009
30
Nephrogenic systemic fibrosis. (18663283)
2009
31
Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI. (19520215)
2009
32
Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. (18401336)
2008
33
Nephrogenic systemic fibrosis and gadolinium: a perfect storm. (18806157)
2008
34
Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. (18690983)
2008
35
Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature. (18324398)
2008
36
Treatment of nephrogenic systemic fibrosis with Re-PUVA. (18625379)
2008
37
Nephrogenic systemic fibrosis: possible association with a predisposing infection. (18356457)
2008
38
Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. (18425843)
2008
39
Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. (18287249)
2008
40
Nephrogenic systemic fibrosis: recommendations for gadolinium-based contrast use in patients with kidney disease. (18226005)
2008
41
Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen. (18290354)
2008
42
Nephrogenic systemic fibrosis and gadolinium: a cautionary tale in the molecular imaging era. (18811752)
2008
43
A timely reminder about an evolving clinical entity: nephrogenic systemic fibrosis and gadolinium use in CKD. (17498132)
2007
44
Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. (17712863)
2007
45
Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: clinical aspects. (17215616)
2007
46
Neuromuscular involvement in nephrogenic systemic fibrosis. (18090682)
2007
47
Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. (17097388)
2007
48
Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. (17213364)
2007
49
Gadolinium-induced nephrogenic systemic fibrosis in patients with kidney disease. (17602923)
2007
50
Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis--setting the record straight. (16461067)
2006

Variations for Nephrogenic Systemic Fibrosis

About this section

Expression for genes affiliated with Nephrogenic Systemic Fibrosis

About this section
Search GEO for disease gene expression data for Nephrogenic Systemic Fibrosis.

Pathways for genes affiliated with Nephrogenic Systemic Fibrosis

About this section

Pathways related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

(show all 48)
idSuper pathwaysScoreTop Affiliating Genes
19.8DCN, SPP1, TGFB1
2
Show member pathways
9.6SMAD4, SMAD7, TGFB1
39.6EDN1, EPO, PIK3CA, TIMP1
49.4SMAD3, SMAD4, TGFB1
59.3DCN, PIK3CA, SMAD2, TGFB1
6
Show member pathways
9.3PIK3CA, SMAD2, SMAD3
79.2PIK3CA, SMAD2, SMAD4, TGFB1
89.1SMAD2, SMAD3, SMAD4
99.1SMAD2, SMAD3, SMAD4
10
Show member pathways
9.1SMAD2, SMAD3, SMAD4
119.1EDN1, EPO, SMAD3, SMAD4
128.9SMAD2, SMAD3, SMAD4, TGFB1
138.9SMAD2, SMAD3, SMAD4, TGFB1
14
Show member pathways
8.9SMAD2, SMAD3, SMAD4, TGFB1
15
Show member pathways
8.9SMAD2, SMAD3, SMAD4, TGFB1
16
Show member pathways
8.9SMAD2, SMAD3, SMAD4, TGFB1
17
Show member pathways
8.9SMAD2, SMAD3, SMAD4, TGFB1
18
Show member pathways
8.9SMAD2, SMAD3, SMAD4, TGFB1
19
Show member pathways
8.9SMAD2, SMAD3, SMAD4, TGFB1
208.9SMAD2, SMAD3, SMAD4, TGFB1
218.9SMAD2, SMAD3, SMAD4, TGFB1
228.9PIK3CA, SMAD2, SMAD3, SMAD4
23
Show member pathways
8.8SMAD2, SMAD3, SMAD4, SMAD7
248.8SMAD2, SMAD3, SMAD4, SMAD7
258.7PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
26
Show member pathways
8.7PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
27
Show member pathways
8.7PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
28
Show member pathways
8.7PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
29
Show member pathways
8.7PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
30
Show member pathways
8.6DCN, SMAD2, SMAD3, SMAD4, TGFB1
318.6SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
32
Show member pathways
8.6SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
338.6SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
348.6SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
35
Show member pathways
8.6SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
368.5EDN1, PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
37
Show member pathways
8.5PIK3CA, SMAD2, SMAD3, SMAD4, SPP1, TGFB1
38
Show member pathways
8.5MAPKAP1, PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
398.5EDNRA, PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
408.4SMAD2, SMAD3, SMAD4, SMAD7, SPP1, TGFB1
41
Show member pathways
8.3DCN, SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
428.3CTGF, SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
438.3CTGF, SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
44
Show member pathways
7.5CCL7, CTGF, EPO, SMAD2, SMAD3, SMAD4
45
Show member pathways
7.4CCL7, CTGF, CXCL2, SMAD3, SMAD4, TGFB1
46
Show member pathways
7.2CCL7, CTGF, PIK3CA, SMAD2, SMAD3, SMAD4
47
Show member pathways
7.0CCL7, CXCL2, EDN1, EDNRA, EPO, SMAD3
48
Show member pathways
6.0CCL7, CXCL2, EDN1, EDNRA, MAPKAP1, PIK3CA

GO Terms for genes affiliated with Nephrogenic Systemic Fibrosis

About this section

Cellular components related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1activin responsive factor complexGO:003244410.4SMAD2, SMAD4
2platelet alpha granule lumenGO:003109310.3F13A1, TGFB1, TIMP1
3SMAD2-SMAD3 protein complexGO:007114410.3SMAD2, SMAD3
4SMAD protein complexGO:00711419.9SMAD2, SMAD3, SMAD4
5extracellular matrixGO:00310129.7DCN, TGFB1, TGM2, TIMP1
6proteinaceous extracellular matrixGO:00055789.7CTGF, DCN, TGFB1, TIMP1
7transcription factor complexGO:00056679.1SMAD2, SMAD3, SMAD4, SMAD7
8extracellular spaceGO:00056157.3CCL7, CTGF, CXCL2, DCN, EDN1, EPO
9extracellular regionGO:00055766.6CCL7, CTGF, CXCL2, DCN, EDN1, EPO

Biological processes related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

(show top 50)    (show all 55)
idNameGO IDScoreTop Affiliating Genes
1artery smooth muscle contractionGO:001482410.7EDN1, EDNRA
2cell activationGO:000177510.7TGFB1, TIMP1
3response to laminar fluid shear stressGO:003461610.7SMAD7, TGFB1
4pathway-restricted SMAD protein phosphorylationGO:006038910.6SMAD7, TGFB1
5response to dexamethasoneGO:007154810.6EDN1, EPO
6histamine secretionGO:000182110.6EDN1, EDNRA
7maternal process involved in parturitionGO:006013710.5EDN1, EDNRA
8response to transforming growth factor betaGO:007155910.5EDN1, SMAD4
9common-partner SMAD protein phosphorylationGO:000718210.5SMAD2, TGFB1
10positive regulation of extracellular matrix assemblyGO:190120310.5SMAD3, TGFB1
11evasion or tolerance of host defenses by virusGO:001904910.5SMAD3, TGFB1
12response to cholesterolGO:007072310.5SMAD2, TGFB1
13positive regulation of SMAD protein import into nucleusGO:006039110.5SMAD4, TGFB1
14positive regulation of odontogenesisGO:004248210.5EDN1, EDNRA, TGFB1
15regulation of epithelial cell proliferationGO:005067810.4EDNRA, SMAD3
16regulation of striated muscle tissue developmentGO:001620210.4SMAD3, TGFB1
17lens fiber cell differentiationGO:007030610.4SMAD3, TGFB1
18regulation of transforming growth factor beta2 productionGO:003290910.3SMAD3, SMAD4
19paraxial mesoderm morphogenesisGO:004834010.3SMAD2, SMAD3
20extracellular matrix disassemblyGO:002261710.2DCN, SPP1, TIMP1
21pericardium developmentGO:006003910.1SMAD2, SMAD3
22nodal signaling pathwayGO:003809210.1SMAD2, SMAD3
23cellular response to transforming growth factor beta stimulusGO:007156010.1EDN1, SMAD7, TGFB1
24response to glucoseGO:000974910.1CTGF, SMAD2, TGFB1
25embryonic foregut morphogenesisGO:004861710.1SMAD2, SMAD3
26positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathwayGO:005148210.0EDN1, EDNRA, TGM2
27positive regulation of inflammatory responseGO:00507299.9CCL7, EDNRA, TGM2
28primary miRNA processingGO:00310539.9SMAD2, SMAD3
29regulation of bindingGO:00510989.6SMAD2, SMAD3, SMAD4, TGFB1
30SMAD protein complex assemblyGO:00071839.6SMAD2, SMAD3, SMAD4, TGFB1
31developmental growthGO:00485899.6SMAD2, SMAD3, SMAD4
32gastrulationGO:00073699.6SMAD2, SMAD3, SMAD4
33SMAD protein signal transductionGO:00603959.6SMAD2, SMAD3, SMAD4, TGFB1
34positive regulation of epithelial to mesenchymal transitionGO:00107189.5SMAD2, SMAD3, SMAD4, TGFB1
35endoderm developmentGO:00074929.4SMAD2, SMAD3, SMAD4, TGFB1
36ureteric bud developmentGO:00016579.4SMAD2, SMAD3, SMAD7, TGFB1
37negative regulation of transforming growth factor beta receptor signaling pathwayGO:00305129.4SMAD2, SMAD3, SMAD7, TGFB1
38agingGO:00075689.3CTGF, DCN, EDNRA, EPO, TGFB1, TIMP1
39wound healingGO:00420609.2DCN, SMAD3, TGFB1, TIMP1
40transforming growth factor beta receptor signaling pathwayGO:00071799.2SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
41positive regulation of cell migrationGO:00303359.2CCL7, EDN1, SMAD3, TGFB1
42positive regulation of ERK1 and ERK2 cascadeGO:00703749.1CCL7, CTGF, EDNRA, EPO
43regulation of transforming growth factor beta receptor signaling pathwayGO:00170159.1SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
44response to lipopolysaccharideGO:00324969.0CXCL2, DCN, EDN1, EDNRA, EPO
45intracellular signal transductionGO:00355569.0CTGF, EDN1, SMAD2, SMAD4, SMAD7
46positive regulation of cell proliferationGO:00082848.9CTGF, EDN1, EDNRA, EPO, TGFB1, TIMP1
47response to hypoxiaGO:00016668.8EDN1, EDNRA, EPO, SMAD3, SMAD4, TGFB1
48in utero embryonic developmentGO:00017018.7EDN1, EDNRA, RCN1, SMAD2, SMAD3, SMAD4
49negative regulation of transcription from RNA polymerase II promoterGO:00001228.1EDN1, EPO, SMAD2, SMAD3, SMAD4, SMAD7
50positive regulation of transcription from RNA polymerase II promoterGO:00459447.8DCN, EDN1, SMAD2, SMAD3, SMAD4, SMAD7

Molecular functions related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1protein-glutamine gamma-glutamyltransferase activityGO:000381010.6F13A1, TGM2
2transcription factor activity, protein bindingGO:000098810.4SMAD3, SMAD4
3transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activityGO:003061810.3SMAD2, SMAD3
4type I transforming growth factor beta receptor bindingGO:003471310.2SMAD2, SMAD7, TGFB1
5enhancer bindingGO:003532610.2SMAD2, SMAD3
6cytokine activityGO:000512510.2EDN1, SPP1, TGFB1, TIMP1
7co-SMAD bindingGO:007041010.2SMAD2, SMAD3
8transforming growth factor beta receptor bindingGO:000516010.0SMAD2, SMAD3, TGFB1
9I-SMAD bindingGO:00704119.9SMAD2, SMAD4, SMAD7
10R-SMAD bindingGO:00704129.9SMAD2, SMAD3, SMAD4
11collagen bindingGO:00055189.5DCN, SMAD3, SMAD4, SMAD7
12protein bindingGO:00055154.1CCL7, CTGF, CXCL2, DCN, EDN1, EDNRA

Sources for Nephrogenic Systemic Fibrosis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet